» Articles » PMID: 30894526

Cryo-EM Structure of a Light Chain-derived Amyloid Fibril from a Patient with Systemic AL Amyloidosis

Overview
Journal Nat Commun
Specialty Biology
Date 2019 Mar 22
PMID 30894526
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Amyloid fibrils derived from antibody light chains are key pathogenic agents in systemic AL amyloidosis. They can be deposited in multiple organs but cardiac amyloid is the major risk factor of mortality. Here we report the structure of a λ1 AL amyloid fibril from an explanted human heart at a resolution of 3.3 Å which we determined using cryo-electron microscopy. The fibril core consists of a 91-residue segment presenting an all-beta fold with ten mutagenic changes compared to the germ line. The conformation differs substantially from natively folded light chains: a rotational switch around the intramolecular disulphide bond being the crucial structural rearrangement underlying fibril formation. Our structure provides insight into the mechanism of protein misfolding and the role of patient-specific mutations in pathogenicity.

Citing Articles

A conformational fingerprint for amyloidogenic light chains.

Paissoni C, Puri S, Broggini L, Sriramoju M, Maritan M, Russo R Elife. 2025; 13.

PMID: 40028903 PMC: 11875538. DOI: 10.7554/eLife.102002.


Multimodality imaging features of systemic amyloidosis: a case report.

Yu Y, Li Z, Li G, Wang T, Li Y BMC Cardiovasc Disord. 2025; 25(1):1.

PMID: 39748274 PMC: 11694375. DOI: 10.1186/s12872-024-04441-6.


Principles and Biomedical Applications of Self-Assembled Peptides: Potential Treatment of Type 2 Diabetes Mellitus.

Mohammad Karim A Pharmaceutics. 2024; 16(11).

PMID: 39598565 PMC: 11597675. DOI: 10.3390/pharmaceutics16111442.


Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis.

Morgan G, Yung Z, Spencer B, Sanchorawala V, Prokaeva T Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598451 PMC: 11597191. DOI: 10.3390/ph17111542.


Antibody Aggregation: A Problem Within the Biopharmaceutical Industry and Its Role in AL Amyloidosis Disease.

Sheehan K, Jeon H, Corr S, Hayes J, Mok K Protein J. 2024; 44(1):1-20.

PMID: 39527351 DOI: 10.1007/s10930-024-10237-6.


References
1.
Buxbaum J, Chuba J, Hellman G, Solomon A, Gallo G . Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med. 1990; 112(6):455-64. DOI: 10.7326/0003-4819-76-3-112-6-455. View

2.
Guerrero-Ferreira R, Taylor N, Mona D, Ringler P, Lauer M, Riek R . Cryo-EM structure of alpha-synuclein fibrils. Elife. 2018; 7. PMC: 6092118. DOI: 10.7554/eLife.36402. View

3.
Sievers F, Wilm A, Dineen D, Gibson T, Karplus K, Li W . Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011; 7:539. PMC: 3261699. DOI: 10.1038/msb.2011.75. View

4.
Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

5.
Merlini G, Comenzo R, Seldin D, Wechalekar A, Gertz M . Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2013; 7(1):143-56. DOI: 10.1586/17474086.2014.858594. View